NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of NRx Pharmaceuticals in a report issued on Tuesday, August 25th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.43) per share for the quarter, down from their prior estimate of ($0.06). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at $0.00 EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at $0.15 EPS, FY2029 earnings at $0.71 EPS and FY2030 earnings at $1.14 EPS.
Several other equities analysts have also recently commented on the stock. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.50.
NRx Pharmaceuticals Trading Down 5.7%
Shares of NRx Pharmaceuticals stock opened at $3.46 on Thursday. The company’s 50-day moving average price is $3.72 and its 200-day moving average price is $3.04. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The company has a market cap of $149.82 million, a price-to-earnings ratio of -6.29 and a beta of 2.18.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Monday, August 17th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million.
Institutional Investors Weigh In On NRx Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. Ethos Financial Group LLC grew its stake in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after buying an additional 4,000 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $107,000. Two Sigma Investments LP raised its position in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. State Street Corp lifted its holdings in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after acquiring an additional 10,700 shares during the last quarter. Finally, Bleakley Financial Group LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth $318,000. 4.27% of the stock is currently owned by institutional investors.
Key Stories Impacting NRx Pharmaceuticals
Here are the key news stories impacting NRx Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating on NRx Pharmaceuticals, signaling that the analyst continues to see potential upside despite the lowered earnings forecasts. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
- Neutral Sentiment: Reported short-interest data showed zero shares sold short on both August 10 and August 25, with a zero-day days-to-cover ratio. Because the figures appear inconsistent and include a “NaN” change, they provide little meaningful signal for investors.
- Negative Sentiment: HC Wainwright lowered its estimated losses for NRx’s third and fourth quarters of 2026 to $0.43 and $0.50 per share, respectively, from previous estimates of $0.06 and $0.07. The revisions suggest analysts expect profitability to deteriorate more than previously anticipated.
- Negative Sentiment: Forecasts for 2027 were also reduced: full-year EPS moved from a $0.67 profit to a $0.50 loss, while estimates for the first three quarters were set at losses of $0.30, $0.15 and $0.05 per share. Fourth-quarter 2027 EPS was reduced to breakeven from a projected $0.36 profit.
- Negative Sentiment: The largest revisions affected the longer-term outlook. HC Wainwright cut EPS estimates from $2.49 to $0.15 for 2028, from $4.51 to $0.71 for 2029, and from $5.76 to $1.14 for 2030. These cuts materially reduce the anticipated earnings growth story and are likely the main reason the stock has been trending lower.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
